Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer

Benzinga33minutes ago

LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial

Businesswire34minutes ago

Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term

Yahoo FinanceDec 10 22:40

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

Zacks Dec 10 22:05

AstraZeneca (AZN) Receives a Hold From Jefferies

TipRanksDec 10 15:36 · Ratings

Astrazeneca (AZN.US) has achieved breakthrough therapy designation for a potential blockbuster ADC.

Astrazeneca (AZN.US) has a potential blockbuster ADC that has been granted breakthrough therapy designation.

Zhitong FinanceDec 10 14:10